Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 2
2 studies reported at therapy level; 2 evidence entries itemised.
RatSpinal cord injuryContusionInbred strain (not further specified)MaleIntraperitoneal
Model: Acute mechanical (impact) spinal cord injury
Leupeptin and E-64c substantially suppressed neurofilament protein degradation at the site of mechanical insult and at sites of secondary axonal degeneration, and facilitated recovery of motor function.
Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.
RatSpinal cord injuryCompressionmale
Model: Acute spinal cord compression at the Th11 level
Leupeptin substantially reduced the extent of axonal damage, by 17 per cent on average.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.
